MKI67 and breast carcinoma: Moreover, Ki-67 ≥ 20% is used as an inclusion criterion in some clinical trials such as the MonarchE which evaluates the efficiency of an adjuvant CDK4/6 inhibitor in early high-risk HR+/HER2− breast cancer patients (25, 26).